In the same period, Porter et al. [35] have developed a multiplex SERS-based immunoassay platform for the detection of two pancreatic cancer biomarkers, here serum carbohydrate antigen 19-9 (CA 19-9)—this one being the only validated biomarker for pancreatic cancer—and matrix metalloproteinase 7 (MMP-7). This evidence concerns the gene MMP7 and pancreatic neoplasm.